These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1906808)

  • 1. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1991; 31 Suppl 1():3-16. PubMed ID: 1906808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report.
    Nakanishi T; Iwata M; Goto I; Kanazawa I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1992; 32 Suppl 1():9-22. PubMed ID: 1425821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
    Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
    Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seven-year follow-up study of bromocriptine therapy for Parkinson's disease.
    Yanagisawa N; Kanazawa I; Goto I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Ogawa N
    Eur Neurol; 1994; 34 Suppl 3():29-35. PubMed ID: 7821333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
    Przuntek H; Welzel D; Schwarzmann D; Letzel H; Kraus PH
    Eur Neurol; 1992; 32 Suppl 1():36-45. PubMed ID: 1425819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress note on Japanese multicenter bromocriptine monotherapy.
    Kuno S
    Eur Neurol; 1993; 33 Suppl 1():3-5. PubMed ID: 8375429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: analysis on the maintenance and the change of the original mode of treatment.
    Nakanishi T; Kanazawa I; Iwata M; Goto I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1992; 32 Suppl 1():23-9. PubMed ID: 1425818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
    Olsson JE
    Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second interim report of the nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Iwata M; Goto I; Kanazawa I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1989; 29 Suppl 1():3-8. PubMed ID: 2714305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
    Bouchard S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):460-5. PubMed ID: 3676921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.